News

  1. Checkpoint Therapeutics to Participate in the H.C. Wainwright Global Investment Conference
  2. Checkpoint Therapeutics Receives Pediatric Investigational Plan Waivers for Cosibelimab from the European Medicines Agency and U.K. Medicines & Healthcare Products Regulatory Agency
  3. Checkpoint Therapeutics Reports First Quarter 2022 Financial Results and Recent Corporate Highlights